Literature DB >> 12893752

NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade.

Crystal Y Koh1, John R Ortaldo, Bruce R Blazar, Michael Bennett, William J Murphy.   

Abstract

Natural killer (NK) cells are composed of subsets characterized by the expression of inhibitory or activating receptors, or both, specific for different major histocompatibility complex (MHC) class I determinants. We have previously shown that inhibitory receptor blockade of syngeneic NK cells was an effective means of ex vivo purging of leukemia-contaminated bone marrow and that the transplantation of mice with the purged bone marrow cells (BMCs) resulted in long-term, relapse-free survival. We have extended the investigation to assess the antitumor effects mediated by NK cells H2-allogeneic to tumor cells. We demonstrate that various tumor cell lines are more susceptible to lysis by H2-allogeneic NK cells than by syngeneic NK cells in vitro even though comparable percentages of Ly49 NK cells were present. Using allogeneic NK cells to purge leukemia-contaminating BMCs before transplantation resulted in a higher proportion of mice with long-term survival than using syngeneic NK cells. Allogeneic NK cells did not suppress hematopoietic reconstitution as measured by granulocyte/monocyte-colony-forming unit (CFU-GM), complete blood count (CBC), and donor chimerism at various days after transplantation. Inhibitory receptor blockade of allogeneic NK cells also significantly increased these antitumor effects at lower NK/tumor ratios compared with those of syngeneic NK cells. These results demonstrate that H2-allogeneic NK cells mediate more potent antitumor effects than syngeneic NK cells without adverse hematologic effects and thus may be useful in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893752     DOI: 10.1182/blood-2003-04-1367

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Natural killer cell tolerance: control by self or self-control?

Authors:  Baptiste N Jaeger; Eric Vivier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

2.  Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.

Authors:  Caroline Sola; Pascale André; Céline Lemmers; Nicolas Fuseri; Cécile Bonnafous; Mathieu Bléry; Nicolai R Wagtmann; François Romagné; Eric Vivier; Sophie Ugolini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-26       Impact factor: 11.205

Review 3.  Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.

Authors:  Nicole C Smits; Tiffany A Coupet; Claire Godbersen; Charles L Sentman
Journal:  Expert Opin Biol Ther       Date:  2016-06-09       Impact factor: 4.388

4.  Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.

Authors:  Hua Zhang; Yongzhi Cui; Nga Voong; Marianna Sabatino; Dave F Stroncek; Sebastien Morisot; Curt I Civin; Alan S Wayne; Bruce L Levine; Crystal L Mackall
Journal:  J Immunother       Date:  2011-03       Impact factor: 4.456

5.  Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Authors:  Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

6.  Use of natural killer cells as immunotherapy for leukaemia.

Authors:  Bartosz Grzywacz; Jeffrey S Miller; Michael R Verneris
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 7.  Positive and negative regulation by NK cells in cancer.

Authors:  Can M Sungur; William J Murphy
Journal:  Crit Rev Oncog       Date:  2014

8.  CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy.

Authors:  Xuan Guo; Tanel Mahlakõiv; Qian Ye; Srinivas Somanchi; Shuyang He; Hemlata Rana; Andrea DiFiglia; Joseph Gleason; William van der Touw; Robert Hariri; Xiaokui Zhang
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.